Methods and use of inducing apoptosis in cancer cells

Patent metadata

Field	Value
Publication number	US-10668028-B2
Application number	US-201514705591-A
Country	US
Kind code	B2
Filing date	May 6, 2015
Priority date	Apr 11, 2008
Publication date	Jun 2, 2020
Grant date	Jun 2, 2020

Abstract

The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

First claim

What is claimed is:

1. A method for normalizing protein expression level of the oncogenic markers Bcl-2, Bax and caspase 3 in a patient with cancer, the method comprising:
(a) administering to the patient a composition comprising a therapeutically effective dose of Coenzyme Q10; and
(b) detecting a protein expression level of the oncogenic markers Bcl-2, Bax and caspase 3 in a tumor sample obtained from the patient after administration of Coenzyme Q10 that is less than 50% different from a normalized oncogenic marker protein expression level,
wherein the normalizing of the protein expression level of the oncogenic markers is achieved by administering the composition comprising a therapeutically effective dose of Coenzyme Q10 to the patient.

2. The method of claim 1 , wherein the protein expression level of the oncogenic markers detected in the tumor sample is less than 25% different from a normalized oncogenic marker protein expression level.

3. The method of claim 1 , wherein the protein expression level of at least one of the oncogenic markers detected in the tumor sample is less than 10% different from a normalized oncogenic marker protein expression level.

4. The method of claim 1 , further comprising detecting a protein expression level of at least one additional oncogenic marker selected from the group consisting of Bid, Mcl-1, and Bcl-xl in a tumor sample from the patient after administration of the Coenzyme Q10.

Assignees

• Berg Llc

Inventors

• Narain Niven Rajin
• Persaud Indushekhar
• Mccook John Patrick

Classifications

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K9/0075

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61K9/127

  Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

• A61K9/02

  Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00) · CPC title

• A61K9/06

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title